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Purpose: Many published reports have demonstrated that early stage 
breast cancer patients need a radiotherapy boost on tumor bed after 
breast conserving surgery (BCS) and whole breast irradiation. Linac-
based IORT boost with electrons was implemented to prevent the 
contamination with subclinical tumor cells in the vicinity of tumor 
site, followed by external beam radiotherapy. A IORT boost may allow 
to reduce the incidence of local recurrence, obtaining good esthetical 
results compared to external beam boost, due to skin sparing. In 
addition to whole breast irradiation (WBI), it has yielded excellent 
long-term results. The aim of this study is to present the long term 
follow up results on local control, esthetic evaluation and toxicity of a 
randomized prospective study on early stage breast cancer patients 
treated with IORT boost of 10 Gy versus the same external beam dose.  
Material and Methods: A randomized prospective study on IORT versus 
external beam boost in early breast cancer patients was carried on in 
our Institution. Primary endpoints of the study were the evaluation of 
local recurrence(LR), toxicity and cosmetic result. 
From April 1999 to April 2004, 244 patients were enrolled: 126 in IORT 
arm (131 treatments for 5 bilateral) and 118 in no IORT arm. The 
average age was 49.2 and 50 7 respectively. 
Toxicity valuation was assessed using EORTC/RTOG scale. The 
cosmetic result was detected on five parameters: hyper-pigmentation, 
telangiectasias, hypertrophic scar, profile asymmetry and difference 
in consistency. 
Results: The median follow-up was 130,6 months (range 96-156 
months). Ten patients were lost at the follow up. Sixty women (24,6%) 
were younger than 45 years, 33 in IORT and 27 in no IORT arm. Two 
and five true local recurrences were observed in IORT and no IORT 
arm respectively. Both of the IORT arm recurrences were observed at 
more than 100 months follow up: one of them (in field) was a 62 years 
old woman, with apT1bN0M0 G2 infiltrating ductal carcinoma (IDC), 
after 100 months and the other (marginal) was a 56 years old 
pT1cN0M0 G3 IDC, after 112 months follow up. A third patient 
presented an ipsilateral out of field recurrence: she was a 72 years old 
with a pT1cN0M0 G3 IDC, after 120 months follow up. The mean time 
to recurrence in no IORT group was earlier (55,2 months). One patient 
was a 46 years old, pre-menopausal, with a pT2N2M0 G3 IDC, after 50 
months; one was a 51, pre-menopausal, pT1cN0M0 G3 medullary 
carcinoma, after 40 months; one patient was 69 pT1cN0M0 G2 IDC 
after 45 months; one was 67, pT1cN0M0 G3 IDC, after 56 months; the 
last was a 71 years old woman, pT1cN0M0 G2 infiltrating lobular 
carcinoma, after 90 months. 
No local failures were observed in the group of IORT pre-menopausal 
women.  
As acute toxicity 12 patients developed post-surgical seromas and 7 
wound healing problems occurred (7,8%). No late complications 
associated with IORT were observed, but three cases of liponecrosis in 
the treatment area. In 5 patients, a secondary mastectomy was 
performed for tumour multi centricity or excessive intraductal 
component. Cosmetic result was very good (objective valuation 92,8% 
good or excellent, subjective valuation 90,2%) and comparable to 
patients treated with external boost (87,4% good or excellent). The 
DFS was 89,1% and 86,4% in IORT and no IORT arm, 22 patients 
developed distant metastasis and 19 died (fourteen of them for 
disease).  
Conclusion: Our data suggest that IORT as anticipated boost after 
breast-conserving surgery can be performed without significant 
morbidity and it’s a reliable alternative to conventional postoperative 
external beam boost,  particularly in younger women, for whom 
published studies indicate higher risk of local recurrence. The 
incidence of recurrence with the IORT boost, for any age, including 
young women, is quite low. Further research is required to clarify 
several issues such as identification of the most appropriate subgroups 
of patients for IORT as boost or complete replacement of 
postoperative radiotherapy. 
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Chemoradiation (CRT) has been shown to lead to downsizing in an 
important part of rectal cancers. In 15-20% of cases even a 
pathological complete response (pCR) occurs. In order to tailor 
treatment at an earlier stage, predictive models are being developed. 
Accurate prediction could enable more individualised surgical 
approaches, including less extensive resection or even a wait-and-see 
policy. Furthermore, also CRT could be tailored based on tumor 
response prediction.  
In our research groups several response prediction models for rectal 
cancer have been developed, mainly based on longitudinal PET-
imaging, on MR imaging and on multifactorial nomograms including 
clinical parameters. Furthermore, an innovative method consists of 
adding CT- based features for pre-treatment response prediction in 
rectal cancer, the so-called “radiomics” approach. More recently, also 
biomarkers have been added to the prediction models, since they can 
add important biological information to the prediction model and can 
be collected very easily in clinical practice. We conclude that imaging 
based models and the nomogram developed based on clinical, 
biological and sequential imaging data can accurately predict tumor 
response, and can be used as a decision support tool for individualized 
treatment approaches including surgery avoidance after prospective 
validation. Inclusion of patients developing a clinical complete 
remission after chemoradiation in a wait and see protocol helps us 
further to identify the group of patients in whom surgery can be safely 
omitted. 
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